Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients
Description
Ursodeoxycholic acid (UDCA) was demonstrated to reduce susceptibility to SARS-CoV-2 infection in vitro and improve infection course in chronic liver diseases. However, real-life evidence is lacking. We analyzed the impact of UDCA on COVID-19 outcomes
